Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ignace Vergote, David Cibula, Matthew Powell et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3 randomized trial evaluated the efficacy and safety of pembrolizumab plus chemotherapy followed by pembrolizumab plus olaparib maintenance in 1367 women with advanced BRCA non-mutated epithelial ovarian cancer. The study found that pembrolizumab-olaparib significantly improved progression-free survival compared to the control group, with a hazard ratio of 0.66 in the CPS (≥10) population and 0.71 in the intention-to-treat population at final analysis.
Key findings
- Pembrolizumab-olaparib improved progression-free survival in the CPS (≥10) population with HR 0.66.
- In the intention-to-treat population, progression-free survival was also significantly improved with HR 0.71.
- 66% of participants in the pembrolizumab-olaparib group experienced grade 3 or higher treatment-related adverse events.
Why it matters
The findings suggest that combining pembrolizumab with olaparib may enhance treatment outcomes for patients with advanced ovarian cancer lacking BRCA mutations, potentially guiding future therapeutic strategies in this population.